Wave Life Sciences, Inc. WVE
2.56 USD -0.16 (-5.88%)
Regular-session close
2.56 0.00 0.00%
After hours · Nov 20, 4:25 PM ET
2.55 Day range 2.79
2.55 52-week range 21.73
- YTD
- -84.94%
- 1 year
- -62.13%
Ownership
Held by insiders 15.50%
Held by institutions 85.60%
Float held by institutions 101.31%
Institutions 330
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kennedy Capital Management, LLC | 0.00% | 429,121 | 2.21M | Jun 29, 2026 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 2.09% | 4,111,308 | 21.21M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.83% | 3,598,451 | 18.57M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.16% | 2,287,103 | 11.80M | Mar 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.07% | 2,107,233 | 10.87M | Mar 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.84% | 1,659,857 | 8.56M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.82% | 1,610,961 | 8.31M | Mar 30, 2026 |
Included in Plus and up
Sign in to see Institutional ownership
How much funds own from their 13F filings, quarter by quarter, and the largest holders.
Free with an account
Sign in to see Insider activity
Two years of insider buying and selling by month, marked on the price.
Included in Plus and up
Sign in to see Congress trading
Every stock trade disclosed by members of the US Senate and House.
Free with an account
Sign in to see CEO compensation
What the chief executive was paid each year, by salary, bonus and stock, beside the company's earnings.
Free with an account
Sign in to see Board of directors
Who sits on the board, who chairs it, and how long each director has served.
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOLNO PAUL B. M.D. | Chief Executive Officer | Sale | Feb 8, 2026 | 275,520 |
| CORRIGAN MARK | Director | Sale | Dec 7, 2025 | 28,815 |
| FRANCIS CHRISTOPHER JOHN | Officer | Conversion of Exercise of derivative security | Feb 25, 2026 | 61,867 |
| GSK PLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 10, 2025 | 0 |
| MORAN KYLE | Chief Financial Officer | Sale | Feb 8, 2026 | 134,385 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 29, 2026 | 0 |
